Aesthetic practitioners in the UK have been asked to tell the body that makes the rules about Botox and dermal fillers to let them know their top five issues so they can deal with them.
Cosmetic Couture and the ACPB has been asked to contribute and are determined our voices will be heard. And we need to galvanise all practitioners to contribute so the arguments aren’t only put forward by medics.
If we do not speak out about what we believe, then we have no right to complain if rules change in the future and we don’t like it.
Many medics are likely to say the top five issues include, that dermal fillers should become a prescription only medicine.
The Medicines and Healthcare products Regulatory Agency (MHRA) has asked the JCCP to co-ordinate the responses – indeed they asked the JCCCP: “Would you be able to use your peers, contacts and networks to gather issues that concern aesthetic practitioners in the UK today, and then review these to compile a list of the (say top five) most pressing issues to share with us? We can then see how to address them in a meaningful way’.”
The issues that the MHRA can deal with only fit into three distinct categories:
Medicines including borderline substances
Medical devices including fillers and energy-based devices
Adverse incident reporting
We believe that the volume of responses is vital and that it is vital, given the way this is being co-ordinated, that the wider voices of non-medics in aesthetics are heard in full, both by the JCCP and the MHRA.
Therefore, we would urge everyone to please list their five most critical concerns with direct reference to the things the MHRA has control over.
For help and or advice please contact ACPB who will be co-ordinating the response from its membership and the wider aesthetic community.
Please submit your five concerns (Or more if you have them) to firstname.lastname@example.org and please make sure they are only in connection with
1. Medicines including borderline substances
2. Medical devices including fillers and energy-based devices
3. Adverse incident reporting